Humana Faces Class Action Amid Poor Financial Results
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 01 2026
0mins
Source: Globenewswire
Humana Inc's stock rose by 5.10% and reached a 52-week high despite the broader market decline, with the Nasdaq-100 down 0.12% and the S&P 500 down 0.11%.
The company is currently facing a securities class action lawsuit due to poor financial results, reporting a benefits expense ratio of approximately 91.4% for Q4 2023 and an adjusted EPS of only $26.09, significantly below expectations. Additionally, Humana's future outlook is pessimistic, with an expected adjusted EPS of only $16 for 2024, which is $10 less than 2023 and well below analysts' expectations of $29. This situation has raised concerns about the company's profitability and legal risks, impacting its reputation and financial stability.
Despite these challenges, Humana's stock has shown resilience, reaching a new high, which may indicate investor speculation or confidence in potential recovery strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HUM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HUM
Wall Street analysts forecast HUM stock price to fall
19 Analyst Rating
6 Buy
12 Hold
1 Sell
Moderate Buy
Current: 362.000
Low
231.00
Averages
290.39
High
344.00
Current: 362.000
Low
231.00
Averages
290.39
High
344.00
About HUM
Humana Inc. provides Humana insurance services and CenterWell health care services. The Company's segments include Insurance and CenterWell. The Insurance segment consists of Medicare benefits, marketed to individuals or directly via group Medicare accounts, as well as its contract with CMS to administer the Limited Income Newly Eligible Transition (LI-NET) prescription drug plan program and contracts with various states to provide Medicaid, dual eligible demonstration, and Long-Term Support Services benefits. This segment also includes products consisting of employer group commercial fully-insured medical and specialty health insurance benefits marketed to individuals and employer groups. The CenterWell segment includes its pharmacy, primary care, and home solutions operations. The segment also includes its strategic partnerships with WCAS to develop and operate senior-focused, payor-agnostic, primary care centers, as well as its minority ownership interest in hospice operations.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Humana Launches Inaugural Resident Physician Scholarship Program
- Scholarship Program Launch: Humana, in partnership with the National Hispanic Medical Association, has initiated the inaugural Resident Physician Scholarship Program, designed to support seven bilingual internal and family medicine residents in Florida, each receiving $10,000 for educational and professional development, significantly addressing the growing need for bilingual physicians to enhance healthcare quality.
- Cultural Responsiveness Enhancement: The scholarship not only provides recipients with a structured mentorship program and experiential learning at CenterWell senior primary care centers but also directly addresses healthcare access barriers in historically under-resourced communities by fostering culturally competent physicians, thereby enhancing community trust.
- Diversity and Equity Focus: According to NHMA, only about 9% of U.S. physicians identify as Hispanic/Latino, despite this group comprising nearly 19% of the population; this program aims to bridge that gap by supporting the Latino physician pipeline, promoting diversity and equity within the healthcare workforce.
- Community Impact: The program's implementation not only improves healthcare access for Florida's nearly 30% Hispanic or Latino population but also empowers resident physicians committed to culturally humble, community-centered care, thereby enhancing the overall quality and accessibility of medical services with significant social implications.
See More
Analysis of S&P 500 Index Fund Investments
- Investment Recommendation: Most financial advisors recommend low-fee S&P 500 index funds like the Vanguard S&P 500 ETF (VOO) and SPDR S&P 500 ETF (SPY) for their convenience, although they are not perfect, they remain a top choice for many investors.
- Concentration Risk: The top 10 components of the S&P 500 account for 39% of its total market value, with weights of 7.43% for Nvidia, 6.59% for Alphabet, and 6.48% for Apple, indicating a high concentration of investor funds in a few companies, which increases market volatility risk.
- Alternative Investment Options: The Invesco S&P 500 Equal Weight ETF (RSP) offers a more balanced investment approach compared to standard market-cap-weighted funds, with a 15-year average annual return of 12%, lower than Vanguard's 14.4%, but may hold its value better during market downturns.
- Long-Term Return Potential: While the Vanguard S&P 500 ETF has higher long-term returns, the Motley Fool analyst team suggests that there are currently 10 other stocks that could provide higher returns, prompting investors to consider these potential high-yield opportunities when making investment decisions.
See More
Analysis of S&P 500 ETF Investments
- Concentration Risk: Standard S&P 500 ETFs like Vanguard and SPDR have their top 10 components accounting for 39% of total market value, despite representing only 2% of the index, indicating a high concentration of funds in a few companies, which may pose greater risks during market volatility.
- Alternative Investment Options: The Invesco S&P 500 Equal Weight ETF offers a balanced investment approach, with quarterly rebalancing that equalizes stock weights; although it has averaged annual gains of 12%, lower than Vanguard's 14.4%, it may provide better resilience during market downturns.
- Market Performance Comparison: The Vanguard S&P 500 ETF is currently priced at $681.95, with a 52-week range of $545.75 to $699.15, while the Invesco ETF is priced at $211.65, highlighting performance differences that investors should consider based on their risk tolerance.
- Long-term Investment Strategy: While S&P 500 ETFs have shown strong performance in recent years, investors should be mindful of concentration risks, especially during market corrections, and consider balanced ETFs as part of a long-term investment strategy for more stable returns.
See More
Humana Stock Shows Signs of Overbought Risk
- Stock Performance Review: Humana's stock has more than doubled since the market bottomed during the U.S.-Iran war on March 30, yet it was identified as one of the overbought stocks in the S&P 500 by the end of the week, indicating potential downside risk.
- Market Volatility Analysis: Despite choppy trading in major U.S. indexes over the past five sessions, the S&P 500 managed to rise for the 10th time in 11 weeks, reflecting complex investor sentiment influenced by geopolitical developments and the SpaceX IPO.
- Healthcare Sector Resilience: UBS noted that the healthcare sector outperformed the S&P 500 on 85% of the days when the benchmark fell by 1% or more over the past year, demonstrating the sector's resilience amid market turbulence.
- Analyst Rating Adjustments: Bank of America raised its price target for J.M. Smucker to $132, implying about a 14% potential upside from Friday's close, reflecting optimistic market expectations for the company's future performance.
See More
Humana to Divest Stake in Gentiva for $900 Million
- Equity Sale Agreement: Humana has entered into a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, valuing the stake at approximately $900 million, indicating a strategic intent to optimize asset allocation.
- Clear Use of Proceeds: The proceeds from this transaction will be used for general corporate purposes, demonstrating Humana's strategy to enhance financial flexibility through asset disposals to support future business growth.
- Transaction Timeline: The deal is expected to close in the third quarter of 2026, with Humana not anticipating a material impact on its 2026 earnings, reflecting confidence in the company's future financial stability.
- Gentiva Business Context: Gentiva provides end-of-life and palliative care services, and Humana's divestiture may influence its strategic positioning in the healthcare sector, particularly in the competitive landscape of elder care services.
See More
Humana to Divest Minority Stake in Gentiva for $900 Million
- Agreement Signed: Humana has signed a definitive agreement with a consortium of investors to divest its minority stake in Gentiva, valued at approximately $900 million, with the transaction expected to close in Q3 2026, and the company does not anticipate a material impact on 2026 earnings from this pending transaction.
- Business Restructuring Context: Humana's ownership in Gentiva stems from its acquisition of the remaining interest in Kindred at Home in 2021, indicating the company's long-standing intention to divest non-core businesses, including hospice and personal health care services, to focus on its core insurance operations.
- Market Leadership: Gentiva, as the nation's largest provider of end-of-life services, operates over 430 locations with thousands of compassionate clinicians and caregivers, and Humana's divestiture will allow it to concentrate on enhancing the quality and efficiency of its insurance services.
- Advisory Support: Guggenheim Securities is acting as financial advisor to Humana, ensuring the smooth execution of the transaction, while the legal advisory team includes Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP, further enhancing the compliance and security of the deal.
See More
Humana Launches Inaugural Resident Physician Scholarship Program
- Scholarship Program Launch: Humana, in partnership with the National Hispanic Medical Association, has initiated the inaugural Resident Physician Scholarship Program, designed to support seven bilingual internal and family medicine residents in Florida, each receiving $10,000 for educational and professional development, significantly addressing the growing need for bilingual physicians to enhance healthcare quality.
- Cultural Responsiveness Enhancement: The scholarship not only provides recipients with a structured mentorship program and experiential learning at CenterWell senior primary care centers but also directly addresses healthcare access barriers in historically under-resourced communities by fostering culturally competent physicians, thereby enhancing community trust.
- Diversity and Equity Focus: According to NHMA, only about 9% of U.S. physicians identify as Hispanic/Latino, despite this group comprising nearly 19% of the population; this program aims to bridge that gap by supporting the Latino physician pipeline, promoting diversity and equity within the healthcare workforce.
- Community Impact: The program's implementation not only improves healthcare access for Florida's nearly 30% Hispanic or Latino population but also empowers resident physicians committed to culturally humble, community-centered care, thereby enhancing the overall quality and accessibility of medical services with significant social implications.
See More
Analysis of S&P 500 Index Fund Investments
- Investment Recommendation: Most financial advisors recommend low-fee S&P 500 index funds like the Vanguard S&P 500 ETF (VOO) and SPDR S&P 500 ETF (SPY) for their convenience, although they are not perfect, they remain a top choice for many investors.
- Concentration Risk: The top 10 components of the S&P 500 account for 39% of its total market value, with weights of 7.43% for Nvidia, 6.59% for Alphabet, and 6.48% for Apple, indicating a high concentration of investor funds in a few companies, which increases market volatility risk.
- Alternative Investment Options: The Invesco S&P 500 Equal Weight ETF (RSP) offers a more balanced investment approach compared to standard market-cap-weighted funds, with a 15-year average annual return of 12%, lower than Vanguard's 14.4%, but may hold its value better during market downturns.
- Long-Term Return Potential: While the Vanguard S&P 500 ETF has higher long-term returns, the Motley Fool analyst team suggests that there are currently 10 other stocks that could provide higher returns, prompting investors to consider these potential high-yield opportunities when making investment decisions.
See More
Analysis of S&P 500 ETF Investments
- Concentration Risk: Standard S&P 500 ETFs like Vanguard and SPDR have their top 10 components accounting for 39% of total market value, despite representing only 2% of the index, indicating a high concentration of funds in a few companies, which may pose greater risks during market volatility.
- Alternative Investment Options: The Invesco S&P 500 Equal Weight ETF offers a balanced investment approach, with quarterly rebalancing that equalizes stock weights; although it has averaged annual gains of 12%, lower than Vanguard's 14.4%, it may provide better resilience during market downturns.
- Market Performance Comparison: The Vanguard S&P 500 ETF is currently priced at $681.95, with a 52-week range of $545.75 to $699.15, while the Invesco ETF is priced at $211.65, highlighting performance differences that investors should consider based on their risk tolerance.
- Long-term Investment Strategy: While S&P 500 ETFs have shown strong performance in recent years, investors should be mindful of concentration risks, especially during market corrections, and consider balanced ETFs as part of a long-term investment strategy for more stable returns.
See More
Humana Stock Shows Signs of Overbought Risk
- Stock Performance Review: Humana's stock has more than doubled since the market bottomed during the U.S.-Iran war on March 30, yet it was identified as one of the overbought stocks in the S&P 500 by the end of the week, indicating potential downside risk.
- Market Volatility Analysis: Despite choppy trading in major U.S. indexes over the past five sessions, the S&P 500 managed to rise for the 10th time in 11 weeks, reflecting complex investor sentiment influenced by geopolitical developments and the SpaceX IPO.
- Healthcare Sector Resilience: UBS noted that the healthcare sector outperformed the S&P 500 on 85% of the days when the benchmark fell by 1% or more over the past year, demonstrating the sector's resilience amid market turbulence.
- Analyst Rating Adjustments: Bank of America raised its price target for J.M. Smucker to $132, implying about a 14% potential upside from Friday's close, reflecting optimistic market expectations for the company's future performance.
See More
Humana to Divest Stake in Gentiva for $900 Million
- Equity Sale Agreement: Humana has entered into a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, valuing the stake at approximately $900 million, indicating a strategic intent to optimize asset allocation.
- Clear Use of Proceeds: The proceeds from this transaction will be used for general corporate purposes, demonstrating Humana's strategy to enhance financial flexibility through asset disposals to support future business growth.
- Transaction Timeline: The deal is expected to close in the third quarter of 2026, with Humana not anticipating a material impact on its 2026 earnings, reflecting confidence in the company's future financial stability.
- Gentiva Business Context: Gentiva provides end-of-life and palliative care services, and Humana's divestiture may influence its strategic positioning in the healthcare sector, particularly in the competitive landscape of elder care services.
See More
Humana to Divest Minority Stake in Gentiva for $900 Million
- Agreement Signed: Humana has signed a definitive agreement with a consortium of investors to divest its minority stake in Gentiva, valued at approximately $900 million, with the transaction expected to close in Q3 2026, and the company does not anticipate a material impact on 2026 earnings from this pending transaction.
- Business Restructuring Context: Humana's ownership in Gentiva stems from its acquisition of the remaining interest in Kindred at Home in 2021, indicating the company's long-standing intention to divest non-core businesses, including hospice and personal health care services, to focus on its core insurance operations.
- Market Leadership: Gentiva, as the nation's largest provider of end-of-life services, operates over 430 locations with thousands of compassionate clinicians and caregivers, and Humana's divestiture will allow it to concentrate on enhancing the quality and efficiency of its insurance services.
- Advisory Support: Guggenheim Securities is acting as financial advisor to Humana, ensuring the smooth execution of the transaction, while the legal advisory team includes Fried, Frank, Harris, Shriver & Jacobson LLP and Manatt, Phelps & Phillips LLP, further enhancing the compliance and security of the deal.
See More
